Insys Therapeutics competitors

Insys Therapeutics Competitors include Assertio Therapeutics, Delcath Systems, Medivir and Bio-Path Holdings.
Add company...
Insys Therapeutics
Insys Therapeutics
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative supportive care products.
Assertio Therapeutics
Assertio Therapeutics
Assertio Therapeutics (formerly Depomed) is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other.
Delcath Systems
Delcath Systems
Delcath Systems is a specialty pharmaceutical and medical device company focused on oncology.
Medivir
Medivir
Medivir researches, develops, and sells pharmaceuticals primarily for the treatment of oncology.
Bio-Path Holdings
Bio-Path Holdings
Bio-Path Holdings is a clinical and preclinical stage oncology focused antisense drug development company.
Founding Date
Founding Date
1998
Founding Date
1995
Founding Date
1988
Founding Date
1988
Founding Date
2007
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Chandler, US HQ
Round Rock, US
Chandler, US
Locations
Newark, US HQ
Locations
New York, US HQ
Galway, IE
Queensbury, US
Locations
Huddinge, SE HQ
Locations
Bellaire, US HQ
Employees
Employees
423
Employees
43411% decrease
Employees
467% increase
Employees
794% decrease
Employees
12
Valuation ($)
Valuation ($)
395.1 m
Valuation ($)
304.3 m
Valuation ($)
1 m
Valuation ($)
N/A
Valuation ($)
4.4 m

Financial

Revenue (est.)
Revenue (est.)
$140.7m (FY, 2017)
Revenue (est.)
$380.7m (FY, 2017)
Revenue (est.)
$2.7m (FY, 2017)
Revenue (est.)
N/A
Revenue (est.)
$37k (FY, 2017)
Cost of goods
Cost of goods
$20.6m (FY, 2017)
Cost of goods
$72.6m (FY, 2017)
Cost of goods
$701k (FY, 2017)
Cost of goods
N/A
Cost of goods
N/A
Gross profit
Gross profit
$120.1m (FY, 2017)
Gross profit
$308.1m (FY, 2017)
Gross profit
$2m (FY, 2017)
Gross profit
N/A
Gross profit
N/A
Net income
Net income
($228m) (FY, 2017)
Net income
($102.5m) (FY, 2017)
Net income
($45.1m) (FY, 2017)
Net income
N/A
Net income
($7m) (FY, 2017)

Funding

Total funding raised
Total funding raised
$ 2.3m
Total funding raised
$ 875m
Total funding raised
$ 42m
Total funding raised
N/A
Total funding raised
$ 2.3m
For sources of this data, please see the company profileDownload Excel

View company profiles

Assertio Therapeutics
HQ
Newark, US
Employees
434↓ 11% decrease

Assertio Therapeutics (formerly Depomed) is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other.

View company
Delcath Systems
HQ
New York, US
Employees
46↑ 7% increase

Delcath Systems is a specialty pharmaceutical and medical device company focused on oncology.

View company
Medivir
HQ
Huddinge, SE
Employees
79↓ 4% decrease

Medivir researches, develops, and sells pharmaceuticals primarily for the treatment of oncology.

View company
Bio-Path Holdings
HQ
Bellaire, US
Employees
12

Bio-Path Holdings is a clinical and preclinical stage oncology focused antisense drug development company.

View company